SCHEMBL3930848

SCHEMBL3930848

COc1cccc(CCc2cc(N)n[nH]2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPO P05164 2/20 0.48
BACE1 P56817 2/20 0.43
NOS1 P29475 1/20 0.40
NOS2 P35228 1/20 0.40
DYRK1A Q13627 1/20 0.39
HSD17B10 Q99714 1/20 0.38
BTK Q06187 1/20 0.37
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
MAPT P10636 1/20 0.35
GFER P55789 1/20 0.35
KDM1A O60341 1/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
FGFR2 P21802 2/20 0.34
FGFR1 P11362 1/20 0.34
FGFR3 P22607 1/20 0.34
ADORA2A P29274 1/20 0.34
ALDH1A1 P00352 2/20 0.33
MITF O75030 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4016522 0.77 DYRK1A (0.40) BACE1DYRK1AHSD17B10NPC1RAB9A
SCHEMBL4012249 0.73 TAAR1 (0.54) BACE1DYRK1AFGFR2FGFR1FGFR3
SCHEMBL27752546 0.73 KDM1A (0.38) MPOBACE1BTKKDM1AMAOA
SCHEMBL4097246 0.72 NOS2 (0.49) NOS1NOS2DYRK1AMAPTFGFR1
SCHEMBL2940008 0.72 MPO (0.43) MPOBACE1NOS1NOS2BTK
SCHEMBL29792045 0.72 MPO (0.43) MPOBACE1NOS1NOS2BTK
SCHEMBL4011604 0.71 HSD17B10 (0.52) DYRK1AHSD17B10MAPTKDM1AALDH1A1
SCHEMBL4016450 0.71 DYRK1A (0.58) MPODYRK1ANPC1RAB9AMAPT
Hydrochloric Acid SCHEMBL28899248 0.71 MPO (0.42) MPOBACE1NOS1NOS2BTK
SCHEMBL27384224 0.71 KDM1A (0.41) MPOBACE1NOS1NOS2KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101501030-A Pyrimidine derivatives useful in the treatment of cancer ASTRAZENECA AB (SE) 2009-08-05 CN disclosed
EP-2044063-A1 PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER Astra Zeneca AB (SE) 2009-04-08 EP disclosed
WO-2008001070-A1 PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-01-03 WO disclosed
US-20080004302-A1 Novel Compounds ASTRAZENECA AB (SE) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004302-A1 Novel Compounds CYP11B2, CYP11B1, CYP46A1 MPO 733/4885BACE1 718/4885NOS1 1302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.